Lapatinib Effective for Inflammatory Breast Cancer: Presented at SABCS
By Charlene Laino
SAN ANTONIO, TX -- December 14, 2006 -- The small-molecule tyrosine kinase inhibitor lapatinib appears to be effective for the treatment of women with aggressive, inflammatory breast cancer, a prospective phase 2 study suggests.
Massimo Cristofanilli, MD, associate professor, department of breast medical oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, reported the findings here on December 14th at the 29th Annual San Antonio Breast Cancer Symposium (SABCS).
Dr. Cristofanilli and colleagues enrolled 35 women who were a median of 53 years of age and diagnosed with previously untreated inflammatory breast cancer. The women were divided into 2 groups: cohort A included 30 women whose tumors overexpressed human epidermal growth factor receptor 2 (HER2); cohort B included 5 women whose tumors were epidermal growth factor receptor (EGFR)-positive but who did not overexpress human epidermal growth factor receptor 2 (HER2)........
Use this link to read the complete story:
Lapatinib Effective for Inflammatory Breast Cancer
No comments:
Post a Comment